Clinical usefulness of the reticulocyte hemoglobin equivalent in children on hemodialysis

Pinto, Diana Di; Paz, Marcos; Adragna, Marta; López, Laura

doi:10.5546/aap.2020.eng.411

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, ROC analysis revealed a valid utility of Ret-He in screening for ID (AUC = 0.771) and IDA (AUC = 0.845). For pediatric patient groups, cut-off values between 26.0 pg and 29.0 pg have been reported with varying sensitivity and specificity (Table 2) [20,21,23,34]. In adults, the use of Ret-He is strongly recommended in states of ID [16,28].…”

Section: Discussionmentioning

confidence: 99%

The Reticulocyte Hemoglobin Equivalent as a Screening Marker for Iron Deficiency and Iron Deficiency Anemia in Children

Neef

Schmitt

Bader

et al. 2021

JCM

View full text Add to dashboard Cite

Background: Iron deficiency (ID) is one of the most common nutritional deficiencies in children worldwide and may result in iron deficiency anemia (IDA). The reticulocyte hemoglobin equivalent (Ret-He) provides information about the current availability of iron in erythropoiesis. This study aims to examine the validation of Ret-He as a screening marker for ID and IDA in children. Methods: Blood samples were retrospectively obtained from medical records. Anemia was defined according to the definition provided by the World Health Organization (WHO) for children. ID was defined by transferrin saturation (TSAT) < 20% and ferritin < 100 ng/mL. Children were classified into four groups: IDA, non-anemia iron deficiency (NAID), control and others. Results: Out of 970 children, 332 (34.2%) had NAID and 278 (28.7%) presented with IDA. Analysis revealed that Ret-He significantly correlates with ferritin (rho = 0.41; p < 0.001), TSAT (rho = 0.66; p < 0.001) and soluble transferrin receptor (sTfR) (rho = −0.72; p < 0.001). For ROC analysis, the area under the curve (AUC) was 0.771 for Ret-He detecting ID and 0.845 for detecting IDA. The cut-off value for Ret-He to diagnose ID was 33.5 pg (sensitivity 90.7%; specificity 35.8%) and 31.6 pg (sensitivity 90.6%; specificity 50.4%) to diagnose IDA. Conclusions: The present study demonstrates Ret-He to be a screening marker for ID and IDA in children. Furthermore, Ret-He can be used as a single screening parameter for ID and IDA in children without considering other iron parameters. Economically, the use of Ret-He is highly relevant, as it can save one blood tube per patient and additional costs.

show abstract

Section: Discussionmentioning

confidence: 99%

The Reticulocyte Hemoglobin Equivalent as a Screening Marker for Iron Deficiency and Iron Deficiency Anemia in Children

Neef

Schmitt

Bader

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Animal studies show that Ret-Hgb has comparable predictive accuracy for prognosticating ID and IDA as the serum iron indices [99]. Ret-Hgb is affected less by inflammation, diurnal variation, or diet than serum iron indices [98,[124][125][126][127]. Additional advantages of Ret-Hgb over serum iron indices are that it can be determined using a small blood volume from a capillary sample and its lower cost [128,129].…”

Section: Reticulocyte Hemoglobin Contentmentioning

confidence: 99%

Biomarkers of Brain Dysfunction in Perinatal Iron Deficiency

Rao

2024

Nutrients

View full text Add to dashboard Cite

Iron deficiency in the fetal and neonatal period (perinatal iron deficiency) bodes poorly for neurodevelopment. Given its common occurrence and the negative impact on brain development, a screening and treatment strategy that is focused on optimizing brain development in perinatal iron deficiency is necessary. Pediatric societies currently recommend a universal iron supplementation strategy for full-term and preterm infants that does not consider individual variation in body iron status and thus could lead to undertreatment or overtreatment. Moreover, the focus is on hematological normalcy and not optimal brain development. Several serum iron indices and hematological parameters in the perinatal period are associated with a risk of abnormal neurodevelopment, suggesting their potential use as biomarkers for screening and monitoring treatment in infants at risk for perinatal iron deficiency. A biomarker-based screening and treatment strategy that is focused on optimizing brain development will likely improve outcomes in perinatal iron deficiency.

show abstract

Reticulocyte Hemoglobin Equivalent has Comparable Predictive Accuracy as Conventional Serum Iron Indices for Predicting Iron Deficiency and Anemia in a Nonhuman Primate model of Infantile Iron Deficiency

Rao

Lubach

Ennis-Czerniak

et al. 2023

The Journal of Nutrition

View full text Add to dashboard Cite

Clinical usefulness of the reticulocyte hemoglobin equivalent in children on hemodialysis

Cited by 5 publications

References 11 publications

The Reticulocyte Hemoglobin Equivalent as a Screening Marker for Iron Deficiency and Iron Deficiency Anemia in Children

The Reticulocyte Hemoglobin Equivalent as a Screening Marker for Iron Deficiency and Iron Deficiency Anemia in Children

Biomarkers of Brain Dysfunction in Perinatal Iron Deficiency

Reticulocyte Hemoglobin Equivalent has Comparable Predictive Accuracy as Conventional Serum Iron Indices for Predicting Iron Deficiency and Anemia in a Nonhuman Primate model of Infantile Iron Deficiency

Contact Info

Product

Resources

About